Literature DB >> 7500360

The binding of 2-deoxy-D-glucose 6-phosphate to glycogen phosphorylase b: kinetic and crystallographic studies.

N G Oikonomakos1, S E Zographos, L N Johnson, A C Papageorgiou, K R Acharya.   

Abstract

Kinetic and crystallographic studies have characterized the effect of 2-deoxy-glucose 6-phosphate on the catalytic and structural properties of glycogen phosphorylase b. Previous work on the binding of glucose 6-phosphate, a potent physiological inhibitor of the enzyme, to T state phosphorylase b in the crystal showed that the inhibitor binds at the allosteric site and induces substantial conformational changes that affect the subunit-subunit interface. The hydrogen-bond from the O-2 hydroxyl of glucose 6-phosphate to the main-chain oxygen of Val40' represents the only hydrogen bond from the sugar to the other subunit, and this interaction appears important for promoting a more "tensed" structure than native T state phosphorylase b. 2-Deoxy-glucose 6-phosphate acts competitively with both the activator AMP and the substrate glucose 1-phosphate, with Ki values of 0.53 mM and 1.23 mM, respectively. The binding of 2-deoxy-glucose 6-phosphate to T state glycogen phosphorylase b in the crystal, has been investigated and the complex phosphorylase b: 2-deoxy-glucose 6-phosphate has been refined to give a crystallographic R factor of 17.3%, for data between 8 A and 2.3 A. 2-Deoxy-glucose 6-phosphate binds at the allosteric site as the a anomer and adopts a different conformation compared to glucose 6-phosphate. The two conformations differ by 160 degrees in the torsion angle about the C-5-C-6 bond. The contacts from the phosphate group are essentially identical to those made by the phosphate of glucose 6-phosphate but the 2-deoxy glucosyl moiety binds in a quite different orientation compared to the glucosyl of glucose 6-phosphate. 2-Deoxy-glucose 6-phosphate can be accommodated in the allosteric site with very little change in the protein, while structural comparisons show that the phosphorylase b: 2-deoxy-glucose 6-phosphate complex structure is overall more similar to a glucose-like complex than to the Glc-6-P complex structure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500360     DOI: 10.1006/jmbi.1995.0665

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

1.  Effects of commonly used cryoprotectants on glycogen phosphorylase activity and structure.

Authors:  K E Tsitsanou; N G Oikonomakos; S E Zographos; V T Skamnaki; M Gregoriou; K A Watson; L N Johnson; G W Fleet
Journal:  Protein Sci       Date:  1999-04       Impact factor: 6.725

2.  A comparative study of ligand-receptor complex binding affinity prediction methods based on glycogen phosphorylase inhibitors.

Authors:  S S So; M Karplus
Journal:  J Comput Aided Mol Des       Date:  1999-05       Impact factor: 3.686

3.  Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarbo xylate.

Authors:  N G Oikonomakos; K E Tsitsanou; S E Zographos; V T Skamnaki; S Goldmann; H Bischoff
Journal:  Protein Sci       Date:  1999-10       Impact factor: 6.725

4.  The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition.

Authors:  E D Lowe; M E Noble; V T Skamnaki; N G Oikonomakos; D J Owen; L N Johnson
Journal:  EMBO J       Date:  1997-11-17       Impact factor: 11.598

5.  Preferential regulation of rabbit cardiac L-type Ca2+ current by glycolytic derived ATP via a direct allosteric pathway.

Authors:  V A Losito; R G Tsushima; R J Diaz; G J Wilson; P H Backx
Journal:  J Physiol       Date:  1998-08-15       Impact factor: 5.182

6.  FR258900, a potential anti-hyperglycemic drug, binds at the allosteric site of glycogen phosphorylase.

Authors:  Costas Tiraidis; Kyra-Melinda Alexacou; Spyros E Zographos; Demetres D Leonidas; Thanasis Gimisis; Nikos G Oikonomakos
Journal:  Protein Sci       Date:  2007-06-28       Impact factor: 6.725

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.